This article was originally published in The Tan Sheet
Executive SummaryLeiner, Insight Pharmaceuticals, Taro Pharmaceuticals among six new active members elected during CHPA's board of directors meeting in New York Nov. 19; three new associate members also join the group. CHPA board elected two directors to fill open slots: Steven LaMonte, Schering-Plough senior VP-marketing, will take seat vacated by Mark Kirn, who recently was promoted to president-international business development at Schering. Lynne Millheiser, Novartis senior VP-OTC business unit, will complete term previously held by Michel Orsinger, whose duties at Novartis keep him too busy for board responsibilities, CHPA says...
You may also be interested in...
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.